Berube Megan N, Robinson Stephanie A, Wan Emily S, Mongiardo Maria A, Finer Elizabeth B, Moy Marilyn L
Research and Development Service, VA Boston Healthcare System, Boston, Massachusetts, United States.
Center for Healthcare Organization and Implementation Research, VA Bedford Healthcare System, Boston, Massachusetts, United States.
Chronic Obstr Pulm Dis. 2024 Jul 25;11(4):369-381. doi: 10.15326/jcopdf.2023.0472.
The relationships between physical activity (PA) and exercise performance and systemic biomarkers in persons with chronic obstructive pulmonary disease (COPD) have not been well characterized. The impact of PA promotion on biomarkers reflecting myocardial stress, systemic inflammation, and muscle injury is unclear.
This secondary analysis used 3 previously published studies in persons with COPD (2 examined a PA intervention that promoted community-based walking for 3 months) to explore these relationships. PA (daily step counts) and exercise performance (6-minute walk test [6MWT]) were assessed. Serum N-terminal pro-β-type natriuretic peptide (NT-proBNP), the soluble receptor for advanced glycation end products (sRAGE), and muscle-type creatine kinase (CKMM) were assayed at baseline and 3 months. General linear models examined associations between PA/exercise performance and systemic biomarkers at baseline and the effect of the PA intervention on change in biomarkers.
Participants included 366 U.S. Veterans: 98% male, mean age 70±8 years, and forced expiratory volume in 1 second percentage predicted 59±21%. Lower baseline NT-proBNP, but not sRAGE or CKMM, was associated with higher daily step count (-0.95pg/ml per 1000 steps/day, =.060) and higher 6MWT distance (-0.80pg/ml per 100 meters, =.001). Change in daily step count, but not 6MWT, was significantly greater in the intervention (789±1864) compared to the control group (-174±1448; =.002). The PA intervention had no significant impact on change in the systemic biomarkers.
Exercise performance is associated with NT-proBNP in persons with COPD. A 3-month community-based walking intervention is not associated with myocardial stress or muscle injury as assessed by NT-proBNP and CKMM, respectively. Clinical Trial Registration: NCT01772082 and NCT02099799.
慢性阻塞性肺疾病(COPD)患者的体力活动(PA)与运动表现及全身生物标志物之间的关系尚未得到充分描述。PA促进对反映心肌应激、全身炎症和肌肉损伤的生物标志物的影响尚不清楚。
这项二次分析使用了3项先前发表的针对COPD患者的研究(其中2项研究考察了一项促进基于社区步行3个月的PA干预措施)来探究这些关系。评估了PA(每日步数)和运动表现(6分钟步行试验[6MWT])。在基线和3个月时检测血清N末端前脑钠肽(NT-proBNP)、晚期糖基化终产物可溶性受体(sRAGE)和肌肉型肌酸激酶(CKMM)。通用线性模型检验了基线时PA/运动表现与全身生物标志物之间的关联以及PA干预对生物标志物变化的影响。
参与者包括366名美国退伍军人:98%为男性,平均年龄70±8岁,1秒用力呼气容积占预计值百分比为59±21%。较低的基线NT-proBNP与较高的每日步数(每1000步/天-0.95pg/ml,P = 0.060)和较长的6MWT距离(每100米-0.80pg/ml,P = 0.001)相关,但与sRAGE或CKMM无关。与对照组(-174±1448;P = 0.002)相比,干预组(789±1864)的每日步数变化显著更大,但6MWT变化不显著。PA干预对全身生物标志物的变化没有显著影响。
COPD患者的运动表现与NT-proBNP相关。一项为期3个月的基于社区的步行干预与分别通过NT-proBNP和CKMM评估的心肌应激或肌肉损伤无关。临床试验注册编号:NCT01772082和NCT02099799。